TN has 97% Covid immunity for senior citizens, reveals serosurvey
Chennai: At least 97% of the elderly in Tamil Nadu have immunity against Covid-19, a serosurvey conducted in April 2025 by the directorate of public health revealed.
The fifth edition of the survey targeted elderly persons in districts including Chennai, Tiruvallur, Tiruvannamalai, Trichy, Dharmapuri, and Kanyakumari.
Tired of too many ads? go ad free now
Preliminary analysis of 1,214 samples from this group showed protective immunity of 97%, Health Minister Ma Subramaniam said here on Wednesday.
The state public health laboratory tested more than 25,000 samples per phase, selected through population proportionate sampling across the state, utilising techniques for uniform collection.
"We saw a boost in immunity since 2020. The first phase in Oct 2020 showed 32% immunity, which rose to 29% in April 2021 and 70% in Aug 2021.
The same year in Dec, immunity was 87%," he said. Officials at the directorate attributed the increase in immunity to a combination of factors, including effective vaccination implemented during the pandemic and natural infection, leading to high immunity.
High seroprevalence means that a large percentage of people in the sample population have antibodies in their blood, Director of Public Health Dr T S Selvavinayagam said.
This indicates they were exposed to the SARS CoV-2 virus, which causes Covid-19, and carry proteins, antibodies produced by the immune system in response to an infection or vaccination. They are a sign that the body encountered the pathogen and mounted an immune response, often leading to some level of protection against future infections, he said."We vaccinated more than 95% of the population with at least one dose of the vaccine.
Tired of too many ads? go ad free now
Besides this, natural infections due to the circulation of weakened mutations such as Omicron sub-lineages of the virus enhanced antibody development further. This could have contributed to hybrid immunity," he added.
Officials said high seroprevalence correlates with a positive public health outcome. "We know the virus has been largely unable to cause severe illness. We don't see Covid-19 causing deaths in people who are infected," he added.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 hours ago
- Time of India
Delhi govt to discontinue bike ambulance service
N ew Delhi: Delhi govt has decided to discontinue the bike ambulance service launched by AAP govt in Feb 2019 after finding it unsuitable in the city's extreme weather conditions. The bike ambulance service was started in 2019 by the previous AAP govt. It was aimed at providing first aid for emergencies at home. The then govt launched 16 first-responder bikes, which operated in east, north-east Delhi, and Shahdara as part of a pilot project. The scheme was halted because of the Covid lockdown in 2020, but there were plans to give it a fresh push last year. Senior officials, however, said that they have now handed over the bikes to the general administration department of Delhi govt, and there have been suggestions if they can be used by the fire department. "Delhi mostly has extreme weather conditions. Also, there is a tendency among patients to call emergency services like ambulances mostly when they are critical. For critical patients, it is difficult to sit on a bike," an official said. The official mentioned that govt would instead focus more on expanding vans as ambulance services. Officials said govt plans to enhance its emergency medical response capabilities by incorporating 103 additional ambulances into the Centralised Accident and Trauma Service (CATS). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo The expansion, which aims to bolster urgent healthcare services across Delhi, includes the procurement of 50 geriatric-friendly advanced life support (ALS) ambulances that will be operated by an outsourced agency, officials said. Private ambulance operators have been invited to submit applications for 53 basic life support (BLS) vehicles, including drivers and qualified paramedical staff. While starting the bike ambulance service, the then AAP govt had said that two-wheelers can reach places where four-wheelers cannot. In many cases requiring medical attention, a few minutes can mean a difference between life and death. "These bike ambulances are handy as they can reach the site quickly in congested areas, provide first aid, and stabilise a patient's condition before an ambulance arrives. They also inform the control room about the case, if required," it said. Officials, however, said that the bike ambulances are more useful in areas with rough terrain where cars cannot reach at all, but in Delhi, that is not the case. These bike ambulances were equipped with kits, weighing 30kg, that contained air splints to immobilise joints, ambu bags for assisted breathing, a glucometer and a pulse oximeter to check a person's blood glucose and oxygen saturation. They also had a manual suction machine to clear airways and foldable transfer sheets to move patients in a narrow stairwell or from a narrow lane to the ambulance. Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .
Time of India
5 hours ago
- Time of India
Bharat Biotech in-licences GSK's Shigella vaccine
Hyderabad: Vaccine maker Bharat Biotech International Limited (BBIL) has in-licensed pharma giant GSK's under development Shigella vaccine candidate, altSonflex1-2-3. The vaccine candidate was being developed by GSK against Shigellosis, a severe form of bacterial diarrhoea that largely affects children aged below five years in low- and middle-income countries. While GSK has already conducted Phase I and II trials in Europe and Africa, Bharat Biotech will take up further development with Phase III clinical trials, regulatory advancement, and large-scale manufacturing, the Hyderabad-based vaccine maker said on Thursday. As part of the agreement, GSK will continue to support the programme by assisting with clinical trial design, securing external funding, and contributing to the access and delivery plans and commercialisation strategy. The vaccine has been developed on the innovative generalised modules for membrane antigens (GMMA) based platform, which uses bacterial outer membranes to deliver the O Antigen to the immune system. "The in-licensed candidate, altSonflex1-2-3, already showed encouraging results in early-stage clinical trials. A Phase 1 study conducted in Europe demonstrated a favourable safety profile and strong immune response," Bharat Biotech said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Toulouse: Nous recherchons des personnes pour tester les nouvelles aides auditives HearPro En savoir plus Undo "Subsequent Phase 2 trials in Africa, including vaccination of 9-month-old infants—the primary target population—reported no safety concerns. Interim results from 2024 confirmed that the candidate met its pre-set immunogenicity goals," it added. Bharat Biotech Executive Chairman Dr Krishna Ella said: "With no approved vaccine currently available for Shigella and antimicrobial resistance on the rise, there is an urgent need for scalable, science-backed solutions focused on low and middle-income countries. This collaboration combines our strengths in innovation, manufacturing, and global health commitment." He pointed out that Bharat Biotech already has a significant presence in vaccines for diarrhoeal infections, including rotavirus, typhoid, polio, non-typhoidal salmonella, cholera, and paratyphi. In 2021, GSK had inked a product transfer agreement for the world's first malaria vaccine, RTS,S, with Bharat Biotech. Follow more information on Air India plane crash in Ahmedabad here . Get real-time live updates on rescue operations and check full list of passengers onboard AI 171 .
Time of India
5 hours ago
- Time of India
Third Covid-related death recorded in MP this year
Indore: A 52-year-old COVID-19 positive woman from Ratlam died late on Wednesday in Indore, marking the third coronavirus related death in the state this year. The woman had severe pre-existing conditions, including TB, bronchitis and high blood pressure. Tired of too many ads? go ad free now Indore health department officials said that the patient was admitted to a private hospital on Sunday after she complained of breathing difficulties. On Tuesday, she was tested positive for COVID-19 infection, after which she was transferred to the isolation ward of govt-run MRTB Hospital. She succumbed to the illness late on Wednesday. While the death occurred in Indore, it will be recorded under Ratlam district's official records. This fatality follows the death of a 44-year-old woman from Khargone on June 6 at MRTB Hospital. She tested positive for COVID-19 shortly after delivering a baby at MTH Hospital. Prior to that, a 74-year-old kidney patient from Indore died at Aurobindo Hospital on April 27. "On Thursday, a total of seven new cases of COVID-19 were reported in Indore," the district epidemiologist Dr Anshul Mishra said, adding that with these new cases, the total number of COVID-19 patients detected in Indore this year has reached 88, including around a dozen patients who are residents of other districts. "Besides, COVID-19 related death toll has reached at three in this calendar year. Of them, one was a resident of Indore while one each were from Khargone and Ratlam," Dr Mishra said. Most of the active patients are currently in home isolation and are reported to be in stable condition, she added. Among the nine COVID-19 patients identified on Tuesday, a 67-year-old elderly person with co-morbidities has been admitted to a private hospital. Similarly, another 50-year-old individual, experiencing breathing difficulties and other complications, has also been hospitalised in a private facility. Indore CMHO Dr Madhav Hasani reassured the public that current COVID-19 patients are exhibiting very mild symptoms, and there is no cause for panic.
